It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.
Aasems Jacob, MD
Advertisement
Articles by Aasems Jacob, MD
Advertisement
Latest Updated Articles
- Optimal Use of Bone-Targeted Agents in Breast Cancer
Published: August 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
4
Clinical Implications Remain After Dasatinib CRL in CML/ALL
5
